Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
stattic
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Max Planck Institute of Biochemistry
Drug class:
STAT3 inhibitor
Related drugs:
‹
BBI608 (4)
BP1003 (2)
NT-157 (2)
TTI-101 oral (2)
JSI-124 (2)
EC-70124 (1)
INB03 (1)
YHO-1701 (1)
niclosamide (1)
CM-728 (0)
DUET-101 (0)
DUET-201 (0)
GLG-302 (0)
HJC0152 (0)
NT219 (0)
OPB-111077 (0)
STAT3 inhibitor (0)
sulforafan alfadex (0)
WP1066 (0)
SK&F106615 (0)
iMX-110 (0)
AZD9150 (0)
ACT001 (0)
BS-HH-002.SA (0)
SHR0302 (0)
VT-11CR (0)
BBI608 (4)
BP1003 (2)
NT-157 (2)
TTI-101 oral (2)
JSI-124 (2)
EC-70124 (1)
INB03 (1)
YHO-1701 (1)
niclosamide (1)
CM-728 (0)
DUET-101 (0)
DUET-201 (0)
GLG-302 (0)
HJC0152 (0)
NT219 (0)
OPB-111077 (0)
STAT3 inhibitor (0)
sulforafan alfadex (0)
WP1066 (0)
SK&F106615 (0)
iMX-110 (0)
AZD9150 (0)
ACT001 (0)
BS-HH-002.SA (0)
SHR0302 (0)
VT-11CR (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
stattic
Sensitive: D – Preclinical
stattic
Sensitive
:
D
stattic
Sensitive: D – Preclinical
stattic
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login